Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party.

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Eolia Brissot, Gesine Bug, Donald Bunjes, Fabio Ciceri, Jesús Duque-Afonso, Matthias Eder, Matthias Edinger, Hermann Einsele, Jürgen Finke, Jacques-Emmanuel Galimard, Pavel Jindra, Mohamad Mohty, Arnon Nagler, Andreas Neubauer, Maud Ngoya, Wolf Rösler, Johannes Schetelig, Dominik Selleslag, Alexandros Spyridonidis, Matthias Stelljes, Eva Maria Wagner-Drouet, Gerald G Wulf

Ngôn ngữ: eng

Ký hiệu phân loại: 283.3 Branches not in communion with the See of Canterbury

Thông tin xuất bản: England : Bone marrow transplantation , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 689346

Thêm vào giỏ Liên kết toàn văn

The treatment of relapsed/refractory acute myeloid leukemia (AML) is associated with a dismal prognosis. The allogeneic hematopoietic cell transplantation (allo-HCT) is frequently performed as salvage therapy. Reduced intensity conditioning protocols have been developed with the aim of reducing the leukemia burden without increasing their toxicity. We compared the reduced intensity conditioning FM140 (fludarabine, 150 mg/m

Tạo bộ sưu tập với mã QR